牛剑钊,张广超,刘倩,许鸣镝.采用平行人工膜测定螺内酯片体外渗透速率的研究[J].中国药事,2021,35(4):415-421 |
采用平行人工膜测定螺内酯片体外渗透速率的研究 |
Research on In Vitro FLUX Tests of Spironolactone Tablets with Parallel Artificial Membrane Permeability Assay |
|
DOI:10.16153/j.1002-7777.2021.04.008 |
中文关键词: 螺内酯片 平行人工膜 口服固体制剂 渗透速率 |
英文关键词: spironolactone tablets PAMPA oral solid preparations FLUX |
基金项目:国家“重大新药创制” 科技重大专项资助项目(编号 2017ZX09101001) |
|
摘要点击次数: 642 |
全文下载次数: 5 |
中文摘要: |
目的:采用平行人工膜对药物体外渗透速率进行研究,预测口服固体制剂药物螺内酯片的人体生物等效性。方法:使用MacroFLUX 药物渗透速率测定仪,模拟空腹和饱腹条件对螺内酯片的渗透速率进行测定。结果:模拟空腹和饱腹条件,螺内酯片的体外渗透速率模拟空腹结果为114.6%~119.6%,模拟饱腹结果为101.5%~107.5%。结论:采用平行人工膜法测定渗透速率可对螺内酯片人体生物等效性试验的预测提供一定帮助。 |
英文摘要: |
Objective: To predict the human bioequivalence of oral solid drug spironolactone tablets by studying in vitro FLUX tests with parallel artificial membrane permeability assay (PAMPA). Methods: The FLUX of spironolactone was determined by MacroFlux permeability test system to simulate the fasting and fed state. Results: The results of FLUX test by simulating the fasting and fed state were 114.6%-119.6% and 101.5%-107.5% respectively. Conclusion: The in vitro FLUX test with parallel artificial membrane permeability assay is helpful to predict the human bioequivalence of oral solid drug spironolactone tablets. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |